Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes. (3rd July 2020)

• Record Type: Journal Article
• Authors: Peiró, Óscar Manuel; Cediel, German; Bonet, Gil; Rojas, Sergio; Quintern, Verónica; Carrasquer, Anna; González-Del-Hoyo, Maribel; Sanz, Esther; Bardají, Alfredo
• Is Part Of: Biomarkers. Volume 25:Number 5(2020)
• Page Start: 402
• Page End: 409
• Publication Date: 2020-07-03
• Subjects: Biomarker -- acute coronary syndrome -- long-term prognosis -- soluble urokinase plasminogen activator receptor -- myocardial infarction; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2020.1778090
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Purpose: The aim of our study was to analyse the long-term prognostic value of soluble urokinase plasminogen activator receptor (suPAR) in the setting of an acute coronary syndrome (ACS). Methods: We included 340 patients with an ACS who underwent coronary angiography and plasma suPAR concentration was measured. Patients were classified into low suPAR concentrations (<2.6 ng/mL) and high suPAR concentrations (≥2.6 ng/mL) and long-term events were evaluated. suPAR prognostic value was assessed beyond a clinical model that included age, GRACE score, estimated glomerular filtration rate, cardiac troponin-I peak and left ventricular ejection fraction <40%. Results: Higher suPAR concentrations were associated with an increased prevalence of cardiovascular risk factors. After multivariate adjustment, suPAR ≥2.6 ng/mL were independently associated with an increased risk of all-cause death (HR 2.3; 95%CI 1.2–4.4; p = .017), major adverse cardiovascular events (MACE) (HR 1.7; 95%CI 1.1–2.5; p = .020) and heart failure (HR 4.1; 95%CI 1.3–12.6; p = .015), but not with myocardial infarction. For long-term all-cause death significant improvement of reclassification and discrimination were seen after addition of suPAR to a clinical model. Conclusions: In the setting of an ACS, suPAR is associated with long-term all-cause death, heart failure and MACE, and provides incremental prognostic value beyond traditional risks factors.